Genovate Biotechnology Co., Ltd. (TPEX:4130)
Taiwan · Delayed Price · Currency is TWD 26.60
+0.75 (2.90%)
May 29, 2026, 1:30 PM CST
Genovate Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 471.48 | 492.41 | 510.86 | 528.51 | 438.76 | 434.25 | |
Revenue Growth (YoY) | -6.23% | -3.61% | -3.34% | 20.46% | 1.04% | -8.14% |
Cost of Revenue | 308.45 | 315.38 | 318.21 | 317.6 | 283.89 | 284.5 |
Gross Profit | 163.03 | 177.02 | 192.65 | 210.92 | 154.87 | 149.75 |
Selling, General & Admin | 122.15 | 112.2 | 109.74 | 110.31 | 106.89 | 95.49 |
Research & Development | 58.11 | 57.91 | 59.49 | 73.61 | 61.88 | 55.43 |
Operating Expenses | 180.25 | 170.11 | 169.22 | 183.91 | 168.76 | 150.92 |
Operating Income | -17.22 | 6.92 | 23.43 | 27.01 | -13.89 | -1.17 |
Interest Expense | -0.62 | -0.68 | -0.52 | -0.27 | -0.28 | -0.25 |
Interest & Investment Income | 7.67 | 6.29 | 6.5 | 5.02 | 2.67 | 1.61 |
Earnings From Equity Investments | -2.27 | -2.26 | -0.96 | -3.88 | 0.29 | 0.14 |
Currency Exchange Gain (Loss) | 0.24 | 0.24 | 0.43 | 0.21 | 0.44 | -0.19 |
Other Non Operating Income (Expenses) | 1.56 | 2.46 | 1.71 | 2.29 | 1.65 | 3.44 |
EBT Excluding Unusual Items | -10.64 | 12.97 | 30.59 | 30.39 | -9.12 | 3.57 |
Gain (Loss) on Sale of Investments | 0.49 | 0.49 | 0.47 | 0.45 | 0.07 | - |
Other Unusual Items | - | - | - | -0.01 | 0.05 | - |
Pretax Income | -10.15 | 13.45 | 31.06 | 30.83 | -9 | 3.57 |
Income Tax Expense | -0.99 | 1.77 | 5.36 | 1.49 | 3.32 | 3.2 |
Net Income | -9.17 | 11.68 | 25.7 | 29.33 | -12.32 | 0.37 |
Net Income to Common | -9.17 | 11.68 | 25.7 | 29.33 | -12.32 | 0.37 |
Net Income Growth | - | -54.54% | -12.39% | - | - | -99.04% |
Shares Outstanding (Basic) | 114 | 114 | 115 | 115 | 113 | 113 |
Shares Outstanding (Diluted) | 114 | 114 | 115 | 115 | 113 | 113 |
Shares Change (YoY) | -0.65% | -0.81% | -0.24% | 1.49% | -0.03% | -0.14% |
EPS (Basic) | -0.08 | 0.10 | 0.22 | 0.26 | -0.11 | 0.00 |
EPS (Diluted) | -0.08 | 0.10 | 0.22 | 0.25 | -0.11 | 0.00 |
EPS Growth | - | -54.55% | -13.69% | - | - | -99.15% |
Free Cash Flow | -36.29 | -11.94 | 24.34 | 56.81 | -22.04 | -35.22 |
Free Cash Flow Per Share | -0.32 | -0.10 | 0.21 | 0.49 | -0.19 | -0.31 |
Dividend Per Share | - | - | 0.100 | 0.143 | 0.167 | 0.333 |
Dividend Growth | - | - | -29.97% | -14.29% | -49.98% | -12.94% |
Gross Margin | 34.58% | 35.95% | 37.71% | 39.91% | 35.30% | 34.48% |
Operating Margin | -3.65% | 1.40% | 4.59% | 5.11% | -3.17% | -0.27% |
Profit Margin | -1.94% | 2.37% | 5.03% | 5.55% | -2.81% | 0.09% |
Free Cash Flow Margin | -7.70% | -2.42% | 4.76% | 10.75% | -5.02% | -8.11% |
EBITDA | 17.16 | 42.03 | 58.01 | 60.9 | 19.94 | 32.33 |
EBITDA Margin | 3.64% | 8.54% | 11.36% | 11.52% | 4.54% | 7.45% |
D&A For EBITDA | 34.38 | 35.12 | 34.58 | 33.9 | 33.83 | 33.5 |
EBIT | -17.22 | 6.92 | 23.43 | 27.01 | -13.89 | -1.17 |
EBIT Margin | -3.65% | 1.40% | 4.59% | 5.11% | -3.17% | -0.27% |
Effective Tax Rate | - | 13.17% | 17.26% | 4.84% | - | 89.57% |